Philippines Pharmaceutical Market Value to Reach $8 Billion by 2020 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Philippines Pharmaceutical Market Value to Reach $8 Billion by 2020



The Philippines pharmaceutical market value will increase from $4.3 billion in 2013 to $8 billion by 2020, at a compound annual growth rate of 9.4%, according to research from GlobalData, a research and consulting firm. According to the company’s latest report, the Philippines have the third largest pharma market among the countries in the Association of Southeast Asian Nations, just after Indonesia and Thailand.

“Although an increasing disease burden, coupled with prevailing high pharmaceutical prices, are providing the necessary investment incentives for the healthcare market in the Philippines, limited access to healthcare facilities and governmental cuts could yet impede further growth in the future,” said Joshua Owide, GlobalData’s director of healthcare industry dynamics.

Furthermore, public health insurance provider Philippine Health Insurance Corporation does not cover the country’s entire population, resulting in the majority of people being unable to afford medicines. Additionally, high spending to overcome basic economic concerns, such as poverty, dependence on imports and high external debt, have left the Philippines government with insufficient funds to finance the development of healthcare infrastructure, according to GlobalData.

Source: GlobalData

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here